

# 38th ACS National Medicinal Chemistry Symposium

## Confirmed Speakers

### Plenary Opening Session: Recent Advances and Emerging Opportunities in Medicinal Chemistry Sponsored by Gilead

#### Rediscovering Macrocycles as a Modality in Drug Discovery (PL02)



Dr Katerina LEFTHERIS  
(VILYA, INC., SF Bay Area, CA, United States)

#### A Synopsis of the Impact of Small Molecules on Human Health and Longevity (PL01)



Dr Nicholas MEANWELL  
(BARUCH S. BLUMBERG INSTITUTE AND UNIVERSITY OF MICHIGAN, Wallingford, CT, United States)

#### Inhibition of Protein Aggregation and the Development of AKV9 (formerly NU-9) for Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases (PL03)



Prof. Richard B. SILVERMAN  
(NORTHWESTERN UNIVERSITY, Evanston, IL, United States)

### Session 1: Advances in Protein Proximity, Induction and Degradation

#### Magnet Biomedicine's TrueGlue Platform: A Systematic Approach Towards the Discovery of Molecular Glues for Therapeutic Intervention (IL06)



Dr Matthew HAYWARD  
(MAGNET BIOMEDICINE, Boston, MA, United States)

#### Hold and Kill: RIPTAC™ Therapeutics Present a Novel Mechanism to Conquer Cancer (IL05)



Dr Kat KAYSER-BRICKER  
(HALDA THERAPEUTICS, New Haven, CT, United States)

#### Stabilization of 14-3-3 Protein-Protein Interactions with Covalent Molecular Glues (IL04)



Dr Markella KONSTANTINIDOU  
(UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, San Francisco, CA, United States)

#### Informatics Accelerated CRBN Glue Lead Discovery (IL02)



Dr Lingling SHEN  
(NOVARTIS, Belmont, United States)

#### Design and Optimisation of Molecular Glue Degraders (IL03)



Dr Magnus WALTER  
(MONTE ROSA THERAPEUTICS, Basel, Switzerland)

# 38th ACS National Medicinal Chemistry Symposium

## Confirmed Speakers

### Ubiquitin Ligases and Molecular Glue Degraders (IL01)



Prof. Ning ZHENG  
(UNIVERSITY OF WASHINGTON, Seattle, WA, United States)

## Session 2: Chemical Perturbation of Methylation towards Anticancer Drug Discovery

### Development of Potent and Specific Inhibitors for Methyltransferases (IL08)



Prof. Rong HUANG  
(PURDUE UNIVERSITY, West Lafayette, IN, United States)

### Discovery of Novel Small-molecule Degraders for Protein Methyltransferases and Development of New Approaches to Target Undruggable Proteins (IL07)



Prof. Jian JIN  
(ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, NY, United States)

### Discovery of MRTX1719, a Synthetic Lethal Approach for the Treatment of MTAP-Deleted Cancers (IL09)



Dr Matthew MARX  
(MIRATI THERAPEUTICS INC, San Diego, United States)

## Session 3: Infectious Disease Drug Discovery

### Targeting Infectious Diseases with Kinase Inhibitors (IL10)



Dr David DREWRY  
(UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, Chapel Hill, NC, United States)

### Development of Quinazolin-4-Ones that Show Efficacy in Lethal Murine Models of Venezuelan and Eastern Equine Encephalitis (IL11)



Dr Jennifer GOLDEN  
(UNIVERSITY OF WISCONSIN, Madison, WI, United States)

### Invention of MK-7602: an Antimalarial Drug Discovery Collaboration (IL12)



Dr John A. MCCAULEY  
(MERCK, West Point, United States)

## Session 4: Targeted Drug Delivery

### Targeted Radionuclide Therapy: the Promise and Challenges of Short-lived Alpha-emitting Actinides (IL15)

# 38th ACS National Medicinal Chemistry Symposium

## Confirmed Speakers



Dr Rebecca ABERGEL  
(UNIVERSITY OF CALIFORNIA, Berkeley, CA, United States)

### Development of a Novel TOPO1 $\alpha$ ADC Platform: from Concept to Pipeline Application (IL13)



Dr Mark PETERSEN  
(ZYMEWORKS, Vancouver, Canada)

### Harnessing the Power of ADCs by Careful Selection of Target, Linker, Payload, Indication, and Combination Partner (IL14)



Dr Sharsti SANDALL  
(PFIZER, Bothell, WA, United States)

## Session 5: Non-catalytic Kinase Function and Pseudokinases as Drug Targets

### Targeting Functional Sites on Pseudokinase Complexes (IL16)



Dr Arvin DAR  
(MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY, United States)

### Discovery of the Tyk2 Pseudokinase Domain as a Drug Target (IL17)



Dr John TOKARSKI  
(BRISTOL MYERS SQUIBB, Princeton, United States)

### Discovery of TAK-279, a Highly Potent and Selective TYK2 Pseudokinase Inhibitor for the Treatment of Autoimmune Diseases, through Structure-based Drug Design (IL18)



Dr Angela TOMS WEST  
(NIMBUS THERAPEUTICS, INC., Franklin, MA, United States)

## Session 6: A Medicinal Chemist's Toolbox

### Metabolism-Driven Drug Design: Role of Metabolite Profiling and Identification in Medicinal Chemistry (IL24)



Dr Deepak DALVIE  
(CRINETICS PHARMACEUTICALS, San Diego, CA, United States)

### Lessons in Proteome-Wide Covalent Drug Discovery (IL23)



Dr Benjamin HORNING  
(VIVIDION THERAPEUTICS INC., San Diego, United States)

# 38th ACS National Medicinal Chemistry Symposium

## Confirmed Speakers

### Non-additivity in Drug Design (IL19)



Dr Bernd KUHN  
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

### The Rise of Targeting Chimeras (TACs): Next-generation Medicines that Preempt Cellular Events (IL20)



Dr Veerabahu SHANMUGASUNDARAM  
(BRISTOL MYERS SQUIBB, Cambridge, MA, United States)

### Kinetic Selectivity? A Missed Opportunity in Drug Discovery? (IL21)



Prof. Peter TONGE  
(STONY BROOK UNIVERSITY, Stony Brook, NY, United States)

### Mechanism-Based Approaches for Targeting Histone Reader Proteins (IL22)



Prof. Marcey WATERS  
(UNIVERSITY OF NORTH CAROLINA, Chapel Hill, NC, United States)

## Session 7: Use of Machine Learning in Drug Discovery

### Machine Learning Guided Design of Peptide-based Antibiotics and Antivirals (IL25)



Dr Gaurav BHARDWAJ  
(UNIVERSITY OF WASHINGTON, Seattle, WA, United States)

### Rapid Identification of HPGD Inhibitors Using Physics-based Machine Learning Methods (IL28)



Dr Leela Sriram DODDA  
(NIMBUS THERAPEUTICS, Boston, United States)

### The Application of AI and ML to Small Molecule Drug Discovery (IL26)



Dr Gavin HIRST  
(ATOMWISE, San Francisco, CA, United States)

### Driving Innovation with Machine Learning: Impact on a Pipeline of Drug Discovery Programs (IL27)



Dr Jennifer KNIGHT  
(SCHRÖDINGER, New York, NY, United States)

### Applying Active Learning in Drug Discovery (IL29)

# 38th ACS National Medicinal Chemistry Symposium

## Confirmed Speakers



Dr Patrick WALTERS  
(RELAY THERAPEUTICS, Cambridge, MA, United States)

### **Generate-make-test: AI-in-the-loop High-throughput Drug Discovery (IL30)**



Dr Matt WELBORN  
(IAMBIC THERAPEUTICS, La Jolla, CA, United States)

## **MEDI Awards Session**

### **Ralph F. Hirschmann Award Lecture**

#### **Rational Design of Protein-Protein Interaction Inhibitors: a Quixotic Quest (AL02)**



Prof. Paramjit ARORA  
(NYU, New York, United States)

### **MEDI Division Award Lecture**

#### **Unlocking Allostery for Drug Discovery (AL01)**



Dr Maria-Jesus BLANCO  
(ATAVISTIK BIO, Cambridge, MA, United States)